WSD0922 News - LARVOL Sigma

||||||||||  WSD0922 / Wayshine Biopharm
Enrollment change:  WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov) -  May 25, 2023
P1, N=51, Recruiting,  Sponsor: Mayo Clinic
N=77 --> 51

||||||||||  WSD0922 / Wayshine Biopharm
Enrollment open:  WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov) -  Apr 28, 2023
P1, N=77, Recruiting,  Sponsor: Mayo Clinic
N=77 --> 51 Suspended --> Recruiting

|||||||||| Tagrisso (osimertinib) / AstraZeneca
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort. (On Demand | Hall A; Poster Bd # 307) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1810;
P1
Preliminary efficacy was observed in patients with osimertinib-resistant NSCLC and EGFRvIII mutant HGA. Enrollment to expansion cohorts is ongoing.

||||||||||  WSD0922 / Wayshine Biopharm
Trial suspension:  WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov) -  Apr 4, 2023
P1, N=77, Suspended,  Sponsor: Mayo Clinic
Enrollment to expansion cohorts is ongoing. Recruiting --> Suspended

||||||||||  WSD0922 / Wayshine Biopharm
Trial completion date, Trial primary completion date:  WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov) -  Aug 5, 2022
P1, N=72, Recruiting,  Sponsor: Mayo Clinic
Recruiting --> Suspended Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024

||||||||||  WSD0922 / Wayshine Biopharm
Enrollment open:  WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov) -  Dec 22, 2019
P1, N=72, Recruiting,  Sponsor: Mayo Clinic
Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024 Not yet recruiting --> Recruiting

||||||||||  WSD0922 / Wayshine Biopharm
New P1 trial:  WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov) -  Dec 12, 2019
P1, N=72, Not yet recruiting,  Sponsor: Mayo Clinic



	Diseases Companies Products Productz Mechanisms of Action Sites